SCHEMBL25291355

SCHEMBL25291355

Cc1cc(C)c(NC2CCN(C(=O)O)C2)c(Br)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNK O75909 4/20 0.39
CDK12 Q9NYV4 4/20 0.39
HSD11B1 P28845 1/20 0.39
GFER P55789 3/20 0.36
HRH4 Q9H3N8 2/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK7 P50613 1/20 0.35
CCNH P51946 1/20 0.35
MNAT1 P51948 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R1 P27986 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HPGD P15428 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25251140 0.85 PIK3CD (0.38) CCNKCDK12HSD11B1CCNA2CDK2
SCHEMBL25739619 0.84 USP30 (0.48) PIK3CDALDH1A1MAPTEHMT2
SCHEMBL25288540 0.84 USP30 (0.48) PIK3CDALDH1A1MAPTEHMT2
SCHEMBL25301262 0.79 GFER (0.35) CCNKCDK12GFERHRH4ALDH1A1
SCHEMBL1848100 0.73 CYP3A4 (0.43) USP2NPSR1HPGDALDH1A1MEN1
SCHEMBL25225248 0.72 MC4R (0.46) CCNKCDK12ALDH1A1MC4R
SCHEMBL25272411 0.72 OPRM1 (0.55) CCNKCDK12ALDH1A1MEN1KMT2A
SCHEMBL16795443 0.72 ROCK2 (0.44) KDM4EHSD17B10USP2NPSR1HPGD
SCHEMBL25286817 0.72 IDH1 (0.49) PIK3CDALDH1A1MAPTEHMT2
SCHEMBL23295792 0.71 CCNK (0.58) CCNKCDK12HSD11B1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 CCNK 2189/4885CDK12 2313/4885HSD11B1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.